124 related articles for article (PubMed ID: 38773281)
1. Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation.
Rathje K; Gagelmann N; Salit RB; Schroeder T; Gurnari C; Pagliuca S; Panagiota V; Rautenberg C; Cassinat B; Thol F; Robin M; Oechsler S; Heuser M; Rubio MT; Maciejewski JP; Reinhardt HC; Scott BL; Kröger N
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38773281
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
[TBL] [Abstract][Full Text] [Related]
4. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
7. Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies.
Turki AT; Klisanin V; Bayraktar E; Kordelas L; Trenschel R; Ottinger H; Steckel NK; Tsachakis-Mück N; Leserer S; Ditschkowski M; Liebregts T; Koldehoff M; Fleischhauer K; Beelen DW
Am J Transplant; 2020 Mar; 20(3):677-688. PubMed ID: 31597002
[TBL] [Abstract][Full Text] [Related]
8. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation.
Tian Z; Man Q; Yang Y; Guan H; Wang Y; Luo R; Wang J
Ann Hematol; 2024 May; 103(5):1729-1736. PubMed ID: 38538977
[TBL] [Abstract][Full Text] [Related]
9. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer RJ; Kim HT; McGuirk J; Horwitz ME; Johnston L; Patnaik MM; Rybka W; Artz A; Porter DL; Shea TC; Boyer MW; Maziarz RT; Shaughnessy PJ; Gergis U; Safah H; Reshef R; DiPersio JF; Stiff PJ; Vusirikala M; Szer J; Holter J; Levine JD; Martin PJ; Pidala JA; Lewis ID; Ho VT; Alyea EP; Ritz J; Glavin F; Westervelt P; Jagasia MH; Chen YB
J Clin Oncol; 2017 Dec; 35(36):4003-4011. PubMed ID: 29040031
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation.
Nikoloudis A; Buxhofer-Ausch V; Aichinger C; Binder M; Hasengruber P; Kaynak E; Wipplinger D; Milanov R; Strassl I; Stiefel O; Machherndl-Spandl S; Petzer A; Weltermann A; Clausen J
Cells; 2023 Jul; 12(14):. PubMed ID: 37508496
[No Abstract] [Full Text] [Related]
11. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
[TBL] [Abstract][Full Text] [Related]
12. Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
Steiner N; Massoud R; Klyuchnikov E; Gagelmann N; Richter J; Niederwieser C; Rathje K; Urbanowicz T; Kunte A; Engelmann J; Ihne C; Lastovytska I; Lindhauer C; Marquard F; Reichard M; Ryzhkova A; Sabauri R; Schäfersküpper M; Seyedi N; Kalogeropoulos G; Heidenreich S; Rudolph I; Zeck G; Janson D; Wolschke C; Ayuk F; Kröger N
Bone Marrow Transplant; 2024 Jun; ():. PubMed ID: 38877098
[TBL] [Abstract][Full Text] [Related]
13. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
14. Clinical study of graft-versus-host disease prophylaxis in unrelated hematopoietic stem cell transplantation for pediatric nonmalignant diseases with different doses anti-human T-lymphocyte immunoglobulin.
Atay D; Akcay A; Yenigurbuz FD; Akinci B; Bagirova K; Hasanova S; Ozturk G
Pediatr Transplant; 2021 Dec; 25(8):e14098. PubMed ID: 34313359
[TBL] [Abstract][Full Text] [Related]
15. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel.
Bonifazi F; Rubio MT; Bacigalupo A; Boelens JJ; Finke J; Greinix H; Mohty M; Nagler A; Passweg J; Rambaldi A; Socie G; Solano C; Walker I; Barosi G; Kröger N
Bone Marrow Transplant; 2020 Jun; 55(6):1093-1102. PubMed ID: 31969678
[TBL] [Abstract][Full Text] [Related]
16. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes.
Bonifazi F; Olivieri J; Sessa M; Dan E; Sinigaglia B; Rizzi S; Motta MR; Bontadini A; Ulbar F; Giudice V; Papayannidis C; Curti A; Chiereghin A; Lazzarotto T; Cavo M; Arpinati M
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2450-2458. PubMed ID: 30026107
[TBL] [Abstract][Full Text] [Related]
18. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients.
Storci G; Barbato F; Ricci F; Tazzari PL; De Matteis S; Tomassini E; Dicataldo M; Laprovitera N; Arpinati M; Ursi M; Maffini E; Campanini E; Dan E; Manfroi S; Santi S; Ferracin M; Bonafe M; Bonifazi F
Front Immunol; 2022; 13():1058739. PubMed ID: 36713433
[TBL] [Abstract][Full Text] [Related]
20. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]